Don’t let the next pandemic meet this pharmaceutical sector

The patent regime in Canada can be significantly improved to match leading countries and motivate innovative pharmaceutical companies to continue developing made-in-Canada medicines.

As the nation gradually recovers from the pandemic, the government should prioritize addressing the longstanding market failure in the pharmaceutical sector by providing competitive funding for research and development, writes Chukwunonso Nwabufo. Image courtesy of Pixabay

Opinion

BY CHUKWUNONSO NWABUFO

June 2, 2021

Having rounded the first year of the COVID-19 pandemic, it is interesting to see that no made-in-Canada COVID-19 medicines or vaccines have been approved for the treatment and prevention of the disease. That, in turn, contributes to the national mortality and morbidit...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy